Effects of Chocolate on Motor Symptoms of Parkinson's Disease
NCT00906763 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23
Last updated 2010-05-26
Summary
Chocolate consumption has long been associated with enjoyment and pleasure. Popular claims confer on chocolate the properties of being a stimulant, relaxant, euphoriant and antidepressant. These possible pharmacological actions might be related to various biogenic amines, such as serotonin, dopamine, tyramine, histamine, phenylethylamine and cannabinoid-like substances. Most amines are metabolized by monoamineoxidase-A (MAO-A) and are therefore unable to pass the blood-brain-barrier. In contrast, phenylethylamine is a direct dopamine releasing ingredient and as a substrate of MAO-B and due to its lipophilic structure even capable to pass the blood-brain-barrier. Within this line, own clinical observations suggested an increased chocolate consumption in patients with Parkinson's disease (PD) compared to healthy subjects and to their pre-disease state.
In a previous study, we assessed the consumption of chocolate and non-chocolate sweets in PD patients and their partners (as household controls) using a self-questionnaire. Consumption of chocolate was significantly higher in PD patients compared to controls, while consumption of non-chocolate sweets was similar in both groups. Our study suggests that chocolate consumption is increased in PD independent of concomitant depressive symptoms measured by BDI-1. Although reasons for increased chocolate consumption in PD remain elusive, it may hypothetically be a consequence of the high content of various biogenic amines as a content of cocoa influencing dopamine metabolism.
Therefore, in the present study we aim to study the effects of dark chocolate with high cocoa content (85%) compared to chocolate without any cocoa (white chocolate) on motor symptoms in PD patients as measured with UPDRS part III (motor score). The principle design of the intervention is similar to the standard pharmacological challenge test for studying effects on motor symptoms in PD (e.g. levodopa challenge test).
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
Chocolate
A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
Sponsors & Collaborators
-
Technische Universität Dresden
lead OTHER
Principal Investigators
-
Martin Wolz, MD · Technische Universität Dresden
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-05-31
- Primary Completion
- 2010-08-31
- Completion
- 2010-10-31
Countries
- Germany
Study Locations
More Related Trials
-
Emotion, Mood and Executive Function in Parkinson's Disease (PD)
NCT01385735 ·Status: UNKNOWN ·Phase: PHASE4
-
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
NCT03295786 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
NCT03252535 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease
NCT01676103 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
How the Loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance
NCT00040196 ·Status: COMPLETED
-
Piracetam for Treatment Tardive Dyskinesia
NCT00190008 ·Status: COMPLETED ·Phase: PHASE3
-
The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease
NCT00696215 ·Status: UNKNOWN ·Phase: PHASE4
-
Treatment of Parkinson's Disease With a Transdermal Skin Patch
NCT00001931 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease
NCT02066571 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.
NCT04273932 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
NCT02224664 ·Status: COMPLETED ·Phase: PHASE1
-
Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease
NCT00623363 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
NCT02172573 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Effects of Mannitol in Parkinson's Disease
NCT03823638 ·Status: UNKNOWN ·Phase: PHASE2
-
Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System
NCT00001365 ·Status: COMPLETED ·Phase: PHASE2
-
Psilocybin Therapy for Depression in Parkinson's Disease
NCT06455293 ·Status: RECRUITING ·Phase: PHASE2
-
Dopaminergic restauratIon by intraVEntriculaire Administration
NCT04332276 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease
NCT00006077 ·Status: COMPLETED ·Phase: PHASE2
-
Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
NCT00537017 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Coenzyme Q10 (CoQ) in Parkinson Disease
NCT00740714 ·Status: TERMINATED ·Phase: PHASE3
-
First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders
NCT02702648 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease
NCT00666653 ·Status: COMPLETED ·Phase: PHASE1
-
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
NCT01485965 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT06021756 ·Status: UNKNOWN ·Phase: PHASE1
-
Treatment of Depression in Parkinson's Disease
NCT01416818 ·Status: UNKNOWN ·Phase: PHASE2